The ROIC trajectory shows minimal improvement from -3.2% in 2024Q1 to -1.1% in 2026Q2, but even the lone positive reading of 1.7% in 2025Q4 appears to be driven by a quarterly operating income swing rather than sustained structural improvement. Asset turnover of 0.24 suggests the company's asset base is generating revenue at a rate that cannot support the fixed cost structure, meaning returns on capital are unlikely to turn positive without a meaningful step-change in either revenue scale or cost reduction. The rising D/E ratio alongside persistent negative returns may indicate that new capital deployment is not creating incremental value, warranting close monitoring of the return profile as debt continues to accumulate.

The 269-day inventory outstanding has improved marginally from a peak of 327 days in 2024Q1, but remains extraordinarily high for a medical device manufacturer and suggests either slow-moving specialty product lines or aggressive inventory build. The cash conversion cycle's decline from 303 days to 240 days over ten quarters appears driven primarily by modest DPO extension rather than genuine operational efficiency gains. Investors should evaluate whether the inventory base can be rationalized without impairing revenue, given that working capital swings of $45M to $55M per quarter have been the dominant driver of operating cash flow volatility.

The P/B of 0.87 and P/S of 0.48 may suggest a deep-value opportunity, but both metrics are distorted by an eroding equity base and a decelerating revenue trajectory, making them unreliable anchors for intrinsic value. The 25.42x forward EV/EBITDA is particularly elevated for a company with no trailing positive EV/EBITDA, implying that consensus EBITDA estimates embed substantial margin recovery from the current operating margin of negative 3.9%. Relative to peers like GMED, which trades at 19.08x P/E with positive ROE of 11.6%, Orthofix's valuation appears to embed a turnaround narrative that the fundamental data does not yet support.

The D/E ratio has risen steadily from 0.24 in 2024Q1 to 0.55 in 2026Q2 while total debt grew 71% to $234.6M, yet interest coverage has deteriorated from -0.99 to -1.21, indicating that debt service costs are growing faster than the operating earnings needed to cover them. D/EBITDA of 12.00 in 2026Q2 is far above levels typically considered sustainable for a mid-cap medtech company, and the absence of positive operating income in nine of ten quarters means refinancing conversations may carry elevated execution risk. The company's current ratio of 2.84 provides a near-term liquidity buffer, but the trajectory of leverage against persistent losses warrants monitoring for covenant pressure or forced equity issuance.